Merck & NewLink Genetics Collaborate in Investigation of Ebola Vaccine10 Dec 2014 • by Natalie Aster
LONDON – Recently, it was announced that Merck and NewLink firmed an agreement for research, development, manufacture, and distribution of Ebola vaccine candidate. The vaccine candidate was developed by the Public Health Agency of Canada and is currently in the phase of clinical trials. In 2015, the US National Institutes of Health plans to initiate a large study to evaluate the safety and efficacy of the Ebola.
As for FY 2013, the worldwide sales of Merck totalled around $44.0 billion, a decline of 7% compared with $47.3 billion in 2012. The sales decline was driven primarily by lower sales of Singulair. The patents that provided the US market exclusivity and market exclusivity in a number of major European markets for Singulair expired in August 2012 and February 2013, respectively, and the Company experienced a significant decline in Singulair sales in those markets thereafter.
Merck & Co., Inc. is a healthcare company that develops and provides prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company sells its products directly to customers and also through its joint ventures. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey. Merck & Co is involved in four key healthcare segments, including Pharmaceuticals, Animal Health, Consumer Care and Alliances segments.
More details on the company’s business, services, strong and weak sides, news and competitors can be found in the report “Merck & Co. Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis” recently published by Market Publishers Ltd.
Merck & Co. Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Date: December, 2014
More company reports featuring SWOT and financial information, industry and competitors analysis can be found in Company Reports Catalogue.